Blog

CancerVax Passes First Test with Flying Colors

Flashpoint Therapeutics Announces $50M KAIMRC Partnership and Clinical Pipeline Expansion

Flashpoint Therapeutics Scientific Founder, Chad Mirkin, Receives 2024 Kavli Prize for Groundbreaking Work on Spherical Nucleic Acids

CancerVax enters agreement with Flashpoint Therapeutics for research on Universal Cancer Treatment platform

CancerVax Taps Flashpoint Therapeutics’ Nanotechnology Platform to Drive Universal Cancer Treatment

Chicago biotech: Seven players advancing the industry

Flashpoint announces signing of MoU with Ministry of Investment of Saudi Arabia to support discussions around our IPO and with King Abdullah International Medical Research Center (كيمارك KAIMRC) for hosting our clinical trials

Joint MoU to Host Clinical Studies in Saudi Arabia Signed

Flashpoint Therapeutics To Transform Cancer Vaccines With Proper Structure Design

Biotech Companies Tap Saudi Arabia for Venture Funding